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Abstract: While tobacco smoking is the main risk factor for chronic obstructive pulmonary 
disease (COPD) only a fraction of smokers go on to develop the disease. We investigated 
the relationship between the insertion (I) – deletion (D) polymorphisms in the Angiotensin 
converting enzyme (ACE) gene and the risk of developing COPD in smokers by determining 
the distribution of the ACE genotypes (DD, ID and II) in 151 life-long male smokers. 74 of 
the smokers had developed COPD (62 ± 2 years; FEV1 44 ± 6 % reference) whereas the rest 
retained normal lung function (56 ± 2 yrs; FEV1 95 ± 3 % reference). In addition, we genotyped 
159 males recruited randomly from the general population. The prevalence of the DD genotype 
was highest (p = 0.01) in the smokers that developed COPD and its presence was associated 
with a 2-fold increase in the risk for COPD (OR 2.2; IC95% 1.1 to 5.5). Surprisingly, the 151 
individuals in the smoking population did not demonstrate Hardy-Weinberg equilibrium unlike 
the 159 recruited from the general population. Our results suggest that ACE polymorphisms are 
associated with both the smoking history of an individual and their risk of developing COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is now the sixth largest cause of 
death in the world and it’s prevalence is expected to increase in the future (Murray 
and Lopez 1997). Tobacco smoking is the main risk factor for COPD but despite this 
only a fraction of smokers go on to develop the disease (Barnes 2000). While it has 
been suggested that susceptibility to tobacco smoke may reﬂ  ect a genetic component 
of the disease (Barnes 1999) the only genetic factor identiﬁ  ed so far in predisposing 
individuals to COPD is the α1-antitrypsin deﬁ  ciency (Silverman and Speizer 1996).
The Angiotensin-converting enzyme (ACE) is a zinc metallo-peptidase that is 
highly expressed in lungs, where it degrades bradykinin and catalyses the formation 
of the Angiotensin II (AII); a powerful vasoconstrictor, inﬂ  ammatory modulator and 
cellular growth factor (Woods et al 2000). ACE activity is increased in COPD (Brice 
et al 1995; Ucar et al 1997) but it remains to be established whether this is a cause or 
consequence of the disease process.
The ACE gene is located in chromosome 17q23 and shows a functional polymor-
phism consisting of an insertion (I) or deletion (D) of a 287bp fragment that determines 
three genotypes (DD, ID and II) (Rigat et al 1992) where the presence of the D allele 
is associated with higher ACE activity (Rigat et al 1990; Busjahn et al 1998; Chagani 
et al 1999; Montgomery et al 1999). Given that previous studies show increased ACE 
activity in COPD patients (Brice et al 1995; Ucar et al 1997) the aim of the present 
study was to test the hypothesis that the DD genotype is more prevalent in smokers 
that develop COPD.International Journal of COPD 2007:2(3) 330
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Methods
Population and ethics
We genotyped 151 male life-long smokers, 74 of whom 
had developed moderate-severe COPD (FEV1 44 ± 6 % 
reference) and the rest retaining normal lung function 
(FEV1 95 ± 3 % reference). All COPD patients were in a 
stable phase of the disease (not having had an exacerbation 
for, at least, three months preceding their inclusion to the 
study. We exclude subjects with other chronic lung diseases 
(asthma, bronchiectasis, lung cancer and interstitial lung 
diseases) and/or chronic extrapulmonary disorders such 
as, diabetes, arterial hypertension, cancer, immune dis-
eases and cardiac, hepatic or renal failure. In addition, we 
genotyped 159 healthy males recruited randomly from the 
general population. All individuals were from the Balearic 
Islands and belonged to the same Caucasian Mediterranean 
ethnic background. Participants were not relatives and all 
gave informed consent to the study that was approved by 
the ethical review board of the Hospital Universitari Son 
Dureta.
Lung function
Forced spirometry (GS, Warren E Collins, Braintree, MA, 
USA) was determined according to international guidelines 
(Sanchis et al 1989) and reference values were those for a 
Mediterranean population (Roca et al 1986).
ACE genotyping
Genomic DNA was extracted from venous blood using 
standard methods (Promega, Madison, WI, USA) and stored 
at –80ºC for subsequent analysis. The ACE genotype was 
determined using the polymerase chain reaction (PCR). 
Since the D allele can be more effectively ampliﬁ  ed than 
the longer I allele, increasing the potential for ID individu-
als to be genotyped as DD (Ueda et al 1996), we used two 
different genotyping methods. Initially, the genotype was 
determined using the method of Rigat et al (1992) where 
the PCR products were a 190 bp (allele D) and a 490 bp (al-
lele I) (Figure 1, Panel a). Subsequently, the genotype was 
conﬁ  rmed with the method described by Evans et al (1994) 
where the ampliﬁ  ed products were a 84 bp (allele D) and a 
65 bp (allele I) (Figure 1, Panel b).
Statistical analysis
Results are shown for continuous variables as mean and its 
standard error, and for discrete variables as percentages. 
Quantitative variables were compared between groups using 
ANOVA. Genotype distributions were compared between 
smokers with and without COPD using Pearson´s Chi-Square 
test, from which the odds ratio (OR) and the 95% conﬁ  dence 
interval (95% CI) were calculated. Genotype frequencies 
were compared with values predicted by Hardy-Weinberg 
equilibrium equation (p2 + 2pq + q2 = 1) by the Chi-Square 
test, where p is frequency of dominant allele D and q is fre-
quency of recessive allele d. A p value of less than 0.05 was 
considered signiﬁ  cant.
Results
Age, smoking exposure and body mass index were similar in 
smokers with and without COPD (Table 1) and, by deﬁ  nition, 
the smokers with COPD showed characteristics of airﬂ  ow 
obstruction (Table 1).
The distribution of the ACE genotypes in smokers that 
developed COPD was signiﬁ  cantly different (p = 0.023) from 
those with normal lung function (Table 2). As hypothesized, 
the DD genotype was found to be more prevalent in patients 
with COPD (36.5% vs.16.9%, p = 0.01) and the presence of 
the DD genotype in a smoker was calculated to give a 2-fold 
increase in the risk of developing COPD (OR 2.2; IC95% 
1.1 to 5.5).
Surprisingly, we found Hardy-Weinberg disequilibrium 
in the smoking population (n = 151, p = 0.001). Deviations 
from this equilibrium can be caused by either genotyping 
errors and/or stratiﬁ  cations within the population being 
studied (Xu et al 2002) and we excluded the ﬁ  rst possibility 
by using two different genotyping techniques. To address 
the second possibility, we further genotyped 159 randomly 
recruited individuals from the same population as our smok-
ers and found their distribution of ACE genotypes to be in 
Hardy Weinberg equilibrium (Table 3). This observation 
further supports the validity of our genotyping techniques but 
more importantly, suggests that smoking may be associated 
with the ACE genotype. In fact, an excess of the heterozygote 
Table 1 Clinical and functional data of the two life-long smoker 
groups
  Smokers with  Smokers with normal 
  COPD (n = 74)  lung function (n = 77)
Age (yr.)  62 ± 2  56 ± 2
Smoking   49 ± 5  42 ± 5
history (pack-yr.)
Body mass index   25 ± 3  27 ± 1
(Kg /m2)
FEV1 (% reference)  44 ± 6  95 ± 3 *
FEV1/FVC (%)  44 ± 3  78 ± 2*
*p < 0.001International Journal of COPD 2007:2(3) 331
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(ID) was found in smokers (p = 0.05) irrespective of whether 
they had developed COPD (Table 3).
Discussion
This study shows that the DD ACE genotype is associated 
with an increased risk of a smoker to developing COPD and, 
unexpectedly, that the ACE heterozygote is more prevalent 
in individuals that smoke.
ACE and COPD
Previous studies have shown an association between ACE 
genotype and several phenotypic characteristics of COPD, 
for example, the development of pulmonary vascular 
remodelling, right ventricular failure and skeletal muscle 
strength (van Suylen et al 1999; Kanazawa et al 2000; 
Hopkinson et al 2004). To our knowledge, however, this is 
the ﬁ  rst study to show that the presence of the DD genotype 
Figure 1 Determination of DD, ID, and II genotypes by PCR. Panel a shows a representative experiment using the method described by Rigat et al (1992). PCR products 
are a 190 bp fragment (D genotype) and a 490 bp fragment (I genotype). Heterozygotes (ID) have both the 190 bp and 490 bp fragments. Panel b shows a representative 
experiment using the method described by Evans et al (1994). PCR products are a 84 bp (D genotype) and a 65 bp (I genotype). Heterozygotes (ID) have both the 84 bp 
and 65 bp fragments.
a
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increases the risk of a smoker developing chronic airﬂ  ow 
obstruction. Plasma ACE activity is increased in COPD 
(Brice et al 1995; Ucar et al 1997) and while we did not 
measure it here the D allele is associated with higher plasma 
ACE activity (Rigat et al 1990; Busjahn et al 1998; Chagani 
et al 1999; Montgomery et al 1999). The high prevalence 
of the DD genotype observed in the smokers that devel-
oped COPD is therefore consistent with increased plasma 
ACE activity in these patients (Brice et al 1995; Ucar et al 
1997). More importantly, our results suggest that the in-
creased ACE activity reported in COPD (Brice et al 1995; 
Ucar et al 1997) can be related to the genotype and is not 
a consequence of the disease (leading to translational or 
post-translational modiﬁ  cation of the protein).
Our study was not designed to investigate the potential 
mechanisms linking the ACE genotype to the pathogenesis 
of COPD. However, several possibilities can be conceived 
to explain a higher risk of COPD among smokers who carry 
the DD genotype. As discussed earlier, the presence of the D 
allele will increase ACE activity (Rigat et al 1990; Busjahn 
et al 1998; Chagani et al 1999; Montgomery et al 1999) and, 
in turn, cause higher Angiotensin II (AII) levels. Increased 
AII levels will contribute to the inﬂ  ammatory response that 
characterizes COPD (Barnes 1999, 2000) by (1) up-regulat-
ing expression of the endothelial adhesion molecules ICAM-
1 and VCAM-1 (Guba et al 2000) and facilitating neutrophil 
retention within the lungs (Selby et al 1991; Keatings and 
Barnes 1997), (2) activating the neutrophil respiratory burst 
and contributing to oxidative stress (Zafari et al 1998), 
(3) enhancing airway hyper-responsiveness (Myou et al 
2000), (4) regulating vascular smooth-muscle cell growth 
and migration (Hatakeyama et al 1994), that may contribute 
to pulmonary hypertension in COPD and (5) modulating 
tissue repair and ﬁ  brosis (Woods et al 2000).
ACE and smoking
We found that our smoking population was in Hardy-
Weinberg disequilibrium and are conﬁ  dent that this did not 
result from genotyping errors or population stratiﬁ  cation due 
to the reasons given previously.
There are a number of assumptions required to evalu-
ate whether the genotype distribution within a population 
fulﬁ  ls the requirements for Hardy – Weinberg equilibrium, 
namely that the gene is located in a somatic chromosome, 
Table 2 Distribution of the ACE genotypes in the different groups studied
 DD  ID  II  Total
Life-long smokers      
 COPD     
  n  27 40 7  74
  %  36.5 54.1 9.5  100
  normal lung function     
  n  13 53 11  77
  %  16.9 68.8 14.3  100
 Total     
  n  40 93 18  151
  %  26.5 61.6 11.9  100
     
General population  n  53 79 27  159
  %  33.3 49.7 17.0  100
Table 3 Allele/Genotype frequencies and test of Hardy-Weinberg (HW) equilibrium
 General  population  Smokers
f(D) 0.581  0.573
f(I) 0.419  0.427
 O  E  X2 P  O  E  X2 P
DD  53 (33.3%)  53.85 (33.9%)  0.01  >0.9  40 (26.5%)  49.5 (32.8%)  1.82  >0.1
ID  79 (49.7%)  77.41 (48.7%)  0.02  >0.5  93 (61.6%)  73.8 (49%)  4.99  0.026
II  27 (17%)  27.91 (17.4%)  0.009  >0.9  18 (11.9%)  27.5 (18.2%)  3.28  >0.05
HW equilibrium      0.039  >0.5      10.09  0.0027
f = observed frequency of each allele (D or I); O = observed genotype numbers; E = expected genotype numbers under a Hardy-Weinberg (HW) equilibrium assumption; 
X2= Chi-square values; P = probability of differenceInternational Journal of COPD 2007:2(3) 333
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the organism has discrete generations, there is random 
mating within a single population and an infinite popula-
tion size (or sufficiently large so as to minimize the effect 
of genetic drift). Finally, there should be experiences 
of no selection, no mutation, and no migration (gene 
flow). We believe all apply in the populations studied 
here; however, replication by different investigators in 
different populations would be welcome to identify any 
causal link between the ACE gene and COPD. Departure 
from Hardy-Weinberg equilibrium also occurs when 
the selection criteria are based on disease-susceptibility 
genotypes rather than on independently selected alleles. 
In fact, marker-disease association can be detected by 
testing for Hardy-Weinberg disequilibrium at a marker 
locus (Nielsen et al 1998). Therefore, to explain the ex-
cess ID genotype observed among smokers (Table 3), we 
propose the existence of linkage disequilibrium between 
the trait of being a life-long smoker and the ACE locus. 
This interpretation is supported by a recent study showing 
that the ACE ID polymorphism influences the amount of 
cigarettes smoked per week (Hubacek et al 2001).
Molecular heterosis occurs when heterozygous subjects 
for a given polymorphism show a signiﬁ  cantly greater or 
lesser effect for a trait than in homozygous subjects for either 
allele. We found molecular heterosis in smokers, where a 
signiﬁ  cant proportion of individuals carried the ID genotype 
(Table 3). It is worth noting here that molecular heterosis 
(and Hardy-Weinberg disequilibrium) has also been found in 
studies of the dopamine D2 receptor gene (DRD2) in smoking 
males (Lee et al 2002; Lee 2003).
The biological basis of nicotine dependence is not fully 
understood, but it is well established that nicotine stimulates 
the central dopamine reward pathway (Pontieri et al 1996; 
Pontieri et al 1998; Alcantara et al 2003). Like nicotine 
(Zhou et al 2001), Angiotensin II also modulates dopa-
mine release in the striatum (Jenkins et al 1997; Zhou et al 
2001) and it is likely that the ACE gene is involved in the 
regulation of the dopamine reward pathway. This provides 
a mechanistic basis for the interpretation of our observation 
of Hardy-Weinberg disequilibrium and molecular heterosis 
in smokers.
Conclusion
Our study shows, ﬁ  rst, that the presence of the DD ACE geno-
type increases the risk of smokers going on to develop COPD 
and, second, that smoking is linked to a Hardy-Weinberg 
disequilibrium in the allelic distribution of the ACE gene 
consistent with it playing a role in smoking addiction.
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